FDA approves Genentech breast cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for late-stage breast cancer, the agency said Friday.
The FDA announced the approval of Genentech’s Kadcyla (ado-trastuzumab emtansine) for HER2-positive breast cancer that has spread to other parts of the body. HER2 is a protein involved in the growth of normal cells but found in increased amounts in some kinds of cancer cells, which contributes to cancer cell growth and survival. Genentech is the U.S. subsidiary of Swiss drug maker Roche.
The drug consists of Genentech’s Herceptin connected to a drug called DM1, which is designed to interfere with cancer cell growth. It is the fourth treatment approved to target the HER2 protein, after Herceptin, GlaxoSmithKline’s Tykerb (lapatinib) and Genentech’s Perjeta (pertuzumab).
GPhA appoints board of directors for 2013
ORLANDO, Fla. — The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.
"We are grateful for the vision and support of the 2012 board of directors, and we are excited to move ahead with our chairman and our 2013 board," GPhA president and CEO Ralph Neas said. "In a time of enormous change and growth for our industry, leadership is critical."
Mylan North America president Tony Mauro was elected as chairman for a second year, having served as chairman in 2012. The GPhA’s rules stipulate that a chairman or chairwoman can be elected for up to two one-year terms.
"I’m honored to have been elected to serve a second term as chairman of GPhA’s board of directors," Mauro said. "The role that the generics industry plans in providing sustainable healthcare solutions for patients in the United States and around the world has never been more important."
The board for this year includes Don DeGolyer, president and CEO of Sandoz US, elected as vice chairman; Craig Wheeler, president and CEO of Momenta Pharmaceuticals, elected as secretary treasurer; Debra Barrett, SVP global government affairs and public policy of Teva Pharmaceuticals; Carole Ben-Maimon, president for global pharmaceuticals of Impax Labs; Doug Boothe, EVP and general manager of Perrigo Pharmaceuticals; Chuck Caprariello, VP corporate communications and government affairs of Ranbaxy; John Ducker, president and CEO of Fresnius-Kabi USA; Jeffrey Glazer, president and CEO of Heritage Pharmaceuticals; Charlie Mayr, global chief communications officer of Actavis; Thomas Moore, U.S. president of Hospira; Chirag Patel, CEO of Amneal Pharmaceuticals; Joseph Renner, president and CEO of Zydus Pharmaceuticals USA; George Stevenson, president and CEO of Kremers-Urban Pharmaceuticals; and Jeff Watson, president of Apotex.
Kerr Drug completes chainwide implementation of PDX pharmacy system
RALEIGH, N.C. — Kerr Drug has rolled out the PDX Enterprise Pharmacy System chainwide, the retail pharmacy chain said.
Kerr said the system would help it focus on "the future of pharmacy," with increased prescription volume and higher patient care requirements.
"We are really investing heavily in our infrastructure," Kerr Drug VP and CIO Joey Dorsett said. "As a regional chain, it hasn’t always been possible to be the first adopters of all the innovative technologies, but it is non-negotiable that we provide pharmacy services with the best of the best. With PDX, we are able to deliver cutting-edge solutions that improve patients’ lives through better technology."
The PDX system features integrated, centralized pharmacy records, improves work processes and efficiencies and helps to lower labor costs through separation of tasks by the pharmacists and technicians, Kerr said.
The company said the completion of the PDX platform alsowould complement its mobile pharmacy system, allowing smartphone users to refill prescriptions, receive pickup and dosage reminders and retrieve their prescription history via mobile.
"Kerr delivers cutting-edge solutions to improve our patients’ health and make their lives easier," Kerr president and CEO Tony Civello said. "The mobile option allows patients to convert their phones into medical wallets … to access a wide range of our pharmacy services."